166-180 of 775
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's RoundtableConsensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's RoundtableTargeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
- advertisement
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
- advertisement
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
